Sourik Beltrán, MD, MBE1,2; Lydia Sit, MD3; Kenneth R. Ginsburg, MD, MSEd3,4
doi : 10.1001/jamapsychiatry.2021.2127
JAMA Psychiatry. 2021;78(11):1181-1182
Yaara Zisman-Ilani, MA, PhD1; Robert M. Roth, PhD2,3; Lisa A. Mistler, MD2,4
doi : 10.1001/jamapsychiatry.2021.2247
JAMA Psychiatry. 2021;78(11):1183-1184
Brittany Quagan, MS1,2; Scott W. Woods, MD1,2; Albert R. Powers, MD, PhD1,2
doi : 10.1001/jamapsychiatry.2021.2315
JAMA Psychiatry. 2021;78(11):1185-1186
Angela M. Haeny, PhD1; Samantha C. Holmes, PhD1,2; Monnica T. Williams, PhD3,4
doi : 10.1001/jamapsychiatry.2021.2329
JAMA Psychiatry. 2021;78(11):1187-1188
John C. Fortney, PhD1,2; Amy M. Bauer, MS, MD1; Joseph M. Cerimele, MPH, MD1; Jeffrey M. Pyne, MD3,4; Paul Pfeiffer, MD5,6; Patrick J. Heagerty, PhD7; Matt Hawrilenko, PhD1; Melissa J. Zielinski, PhD3; Debra Kaysen, PhD8; Deborah J. Bowen, PhD9; Danna L. Moore, PhD10; Lori Ferro, MHA1; Karla Metzger, MSW5; Stephanie Shushan, MHA11; Erin Hafer, MPH11; John Paul Nolan, AAS12; Gregory W. Dalack, MD5; Jürgen Unützer, MPH, MD1
doi : 10.1001/jamapsychiatry.2021.2318
JAMA Psychiatry. 2021;78(11):1189-1199
Only one-third of patients with complex psychiatric disorders engage in specialty mental health care, and only one-tenth receive adequate treatment in primary care. Scalable approaches are critically needed to improve access to effective mental health treatments in underserved primary care settings.
Ryan J. Van Lieshout, MD, PhD1; Haley Layton, MPH2; Calan D. Savoy, MSc1; June S. L. Brown, PhD3; Mark A. Ferro, PhD4; David L. Streiner, PhD1; Peter J. Bieling, PhD1; Andrea Feller, MD5; Steven Hanna, PhD6
doi : 10.1001/jamapsychiatry.2021.2488
JAMA Psychiatry. 2021;78(11):1200-1207
Postpartum depression (PPD) affects as many as 20% of mothers, yet just 1 in 10 of these women receives evidence-based treatment. The COVID-19 pandemic has increased PPD risk, reduced treatment access, and shifted preferences toward virtual care.
Guillaume Fond, MD, PhD1,2; Katlyn Nemani, MD3; Damien Etchecopar-Etchart, MD1; Anderson Loundou, PhD1; Donald C. Goff, MD3; Seung Won Lee, MD, PhD4; Christophe Lancon, MD, PhD1,2; Pascal Auquier, MD, PhD1; Karine Baumstarck, MD, PhD1; Pierre-Michel Llorca, MD, PhD2,5; Dong Keon Yon, MD6; Laurent Boyer, MD, PhD1,2
doi : 10.1001/jamapsychiatry.2021.2274
JAMA Psychiatry. 2021;78(11):1208-1217
Heterogeneous evidence exists for the association between COVID-19 and the clinical outcomes of patients with mental health disorders. It remains unknown whether patients with COVID-19 and mental health disorders are at increased risk of mortality and should thus be targeted as a high-risk population for severe forms of COVID-19.
Brandon Nichter, PhD1; Melanie L. Hill, PhD1,2; Peter J. Na, MD, MPH3; Alexander C. Kline, PhD1,2; Sonya B. Norman, PhD1,4,5; John H. Krystal, MD3; Steven M. Southwick, MD3; Robert H. Pietrzak, PhD, MPH3,6,7
doi : 10.1001/jamapsychiatry.2021.2332
JAMA Psychiatry. 2021;78(11):1218-1227
The COVID-19 pandemic has raised considerable concerns about increased risk for suicidal behavior among US military veterans, who already had elevated rates of suicide before the pandemic.
Hannah N. Ziobrowski, PhD, MPH1; Chris J. Kennedy, PhD2; Berk Ustun, PhD3; Stacey L. House, MD, PhD4; Francesca L. Beaudoin, MD, PhD5; Xinming An, PhD6; Donglin Zeng, PhD7; Kenneth A. Bollen, PhD8; Maria Petukhova, PhD1; Nancy A. Sampson, BA1; Victor Puac-Polanco, MD, DrPH1,9; Sue Lee, MA1; Karestan C. Koenen, PhD10; Kerry J. Ressler, MD, PhD11,12; Samuel A. McLean, MD, MPH6,13; Ronald C. Kessler, PhD1; and the AURORA Consortium
doi : 10.1001/jamapsychiatry.2021.2427
JAMA Psychiatry. 2021;78(11):1228-1237
A substantial proportion of the 40 million people in the US who present to emergency departments (EDs) each year after traumatic events develop posttraumatic stress disorder (PTSD) or major depressive episode (MDE). Accurately identifying patients at high risk in the ED would facilitate the targeting of preventive interventions.
Stefan Leucht, MD1,2; Sofia Bauer, Cand Med1,3; Spyridon Siafis, MD1; Tasnim Hamza, MSc4; Hui Wu, MD1,5; Johannes Schneider-Thoma, MD1; Georgia Salanti, PhD4; John M. Davis, MD6,7
doi : 10.1001/jamapsychiatry.2021.2130
JAMA Psychiatry. 2021;78(11):1238-1248
The doses of antipsychotic drugs needed for relapse prevention in schizophrenia is a debated issue.
Mariella Henderson, MSc1; Helen Bould, PhD2,3; Eirini Flouri, PhD4; Amy Harrison, PhD4; Gemma Lewis, PhD1; Glyn Lewis, PhD1; Ramya Srinivasan, BMBCh1; Jean Stafford, PhD1; Naomi Warne, PhD2; Francesca Solmi, PhD1
doi : 10.1001/jamapsychiatry.2021.1599
JAMA Psychiatry. 2021;78(11):1249-1257
People with anorexia nervosa often experience difficulties regulating their emotions. There is no longitudinal evidence as to whether these differences are already present in childhood or when they begin to emerge.
Olga Giannakopoulou, PhD1; Kuang Lin, PhD2; Xiangrui Meng, PhD1; Mei-Hsin Su, PhD3; Po-Hsiu Kuo, PhD3,4; Roseann E. Peterson, MD5; Swapnil Awasthi, MSc6; Arden Moscati, MSc7; Jonathan R. I. Coleman, PhD8,9; Nick Bass, MD1; Iona Y. Millwood, DPhil2,10; Yiping Chen, DPhil2,10; Zhengming Chen, DPhil2,10; Hsi-Chung Chen, MD, PhD4; Mong-Liang Lu, MD, MS11,12; Ming-Chyi Huang, MD, PhD12,13; Chun-Hsin Chen, MD, PhD11,12; Eli A. Stahl, PhD14; Ruth J. F. Loos, PhD7,15; Niamh Mullins, PhD14; Robert J. Ursano, MD16; Ronald C. Kessler, MD17; Murray B. Stein, MD, MPH18; Srijan Sen, MD, PhD19; Laura J. Scott, PhD20; Margit Burmeister, PhD21; Yu Fang, MSE22; Jess Tyrrell, PhD23; Yunxuan Jiang, PhD24; Chao Tian, PhD24; Andrew M. McIntosh, PhD25; Stephan Ripke, MD6,26,27; Erin C. Dunn, ScD, MPH17,27,28; Kenneth S. Kendler, MD5; Robin G. Walters, PhD2,10; Cathryn M. Lewis, PhD8,9; Karoline Kuchenbaecker, PhD1,29; for the 23andMe Research Team, China Kadoorie Biobank Collaborative Group, and Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
doi : 10.1001/jamapsychiatry.2021.2099
JAMA Psychiatry. 2021;78(11):1258-1269
Most previous genome-wide association studies (GWAS) of depression have used data from individuals of European descent. This limits the understanding of the underlying biology of depression and raises questions about the transferability of findings between populations.
James A. Blumenthal, PhD1; Patrick J. Smith, PhD1; Wei Jiang, MD1; Alan Hinderliter, MD2; Lana L. Watkins, PhD1; Benson M. Hoffman, PhD1; William E. Kraus, MD3; Lawrence Liao, MD3; Jonathan Davidson, MD1; Andrew Sherwood, PhD1
doi : 10.1001/jamapsychiatry.2021.2236
JAMA Psychiatry. 2021;78(11):1270-1278
Anxiety is common among patients with coronary heart disease (CHD) and is associated with worse health outcomes; however, effective treatment for anxiety in patients with CHD is uncertain.
Michael William Flores, PhD, MPH1,2,3; Margo Moyer, BA1; Caryn R. R. Rodgers, PhD2,4,5; Benjamin Lê Cook, PhD, MPH1,2,3
doi : 10.1001/jamapsychiatry.2021.2485
JAMA Psychiatry. 2021;78(11):1279-1280
Felicia Hung, MPH1; Joshua D. Wallach, PhD, MS1; Stephanie S. O’Malley, PhD2; Krysten W. Bold, PhD2
doi : 10.1001/jamapsychiatry.2021.2468
JAMA Psychiatry. 2021;78(11):1280-1283
Fan-Hsuan Kung, MD1; Mu-Hong Chen, MD2; Chih-Sung Liang, MD1
doi : 10.1001/jamapsychiatry.2021.2787
JAMA Psychiatry. 2021;78(11):1283-1284
Matthew D. Albaugh, PhD1; Max M. Owens, PhD1; Hugh Garavan, PhD1
doi : 10.1001/jamapsychiatry.2021.2790
JAMA Psychiatry. 2021;78(11):1284-1285
doi : 10.1001/jamapsychiatry.2021.2711
JAMA Psychiatry. 2021;78(11):1285
doi : 10.1001/jamapsychiatry.2020.3206
JAMA Psychiatry. 2021;78(11):e203206
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟